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Letter to the EditorA novel IKAROS haploinsufficiency
kindred with unexpectedly late and
variable B-cell maturation defectsTo the Editor:
IKAROS, encoded by the IKAROS family zinc finger protein 1
(IKZF1) gene, is a hematopoietic zinc finger transcription factor
essential in human hematopoiesis and B-cell development.1 So-
matic changes in IKZF1 have been associated with B-cell leuke-
mia.1 Germline IKZF1mutations have been identified recently as
a cause of common variable immunodeficiency and dysgamma-
globulinemia through IKAROS haploinsufficiency.2,3 They are
autosomal dominantly inherited or appear de novo.2-4 Eleven of
42 germline IKZF1 mutation carriers were clinically asymptom-
atic at the time of publication, suggesting incomplete pene-
trance.2-4 However, since age of onset ranged from infancy to
the sixth decade, younger asymptomatic subjects might still
develop disease later in life.2,3 Symptomatic subjects mainly pre-
sented with bacterial infections, especially of the respiratory
tract.2,3 In addition, some patients had antibody-mediated autoim-
mune manifestations or B-cell acute lymphoblastic leukemia.2,3
Affected subjects typically showed a (progressive) decrease of pe-
ripheral B-cell numbers accompanied by a (progressive) reduc-
tion in at least one major immunoglobulin isotype.2,3 Total T-
cell numbers were not decreased, but patients often displayed
quantitative changes in various T-cell subsets.2,3 Here we report
an autosomal dominant kindred with a novel truncating mutation
in IKZF1 and describe new insights in B-cell maturation in 2
symptomatic and 1 asymptomatic family members.
The parents (subjects I:1 and I:2) were healthy and non-
consanguineous and of Dutch-Italian origin (Fig 1, A). Subject
II:3, currently 17 years old, was given a diagnosis of monocyclic
systemic-onset juvenile idiopathic arthritis at the age of 6 years
and reactive arthritis at the age of 9 years. Test results for autoan-
tibodies were negative. Her younger sister (subject II:4, currently
12.5 years old) had multiple episodes of reactive arthritis between
the ages of 3 and 5 years. In addition, both patients had recurrent
bacterial sinopulmonary infections. Patient II:4 was given a
recent diagnosis of juvenile myasthenia gravis confirmed by pos-
itive acetylcholine receptor autoantibody levels.
The immunologic workup of patients II:3 and II:4 is provided
in Table E1 and Figure E1 in this article’s Online Repository at
www.jacionline.org. In summary, patient II:3, who was first
examined at the age of 9 years, had absent serum IgA and IgM
and severe B lymphopenia (Fig 2, A). Patient II:4, who was first
evaluated at 4.5 years of age, had absent IgA but normal IgM
levels. Her B-cell counts were initially in the lower normal range
but decreased progressively over time (Fig 2, A). Both patients
had poor polysaccharide vaccination responses. Total IgG and
IgG subclass levels have thus far remained normal. There were
no important abnormalities in peripheral T-cell subsets. The
youngest sibling (subject II:5) is currently 8 years old and in
good health.
Whole-exome sequencing revealed a heterozygous frameshift
mutation in IKZF1 (NM_006060: c.136delA, p.S46Afs*14) in
the 2 affected siblings (patients II:3 and II:4) and asymptomatic
mother (subject I:2; Fig 1, A). The mutation is not reported inpublic or in-house databases. The frameshift introduces a prema-
ture stop codon before the first zinc finger motif in all IKZF1 tran-
scripts (Fig 1. B). Although nonsense-mediatedmRNA decay was
predicted in silico, mutant transcripts were detected at cDNA
level (see Fig E2 in this article’s Online Repository at www.
jacionline.org), and patients had normal levels of IKZF1 cDNA
(Fig 1, C), suggesting mutant transcripts escape nonsense-
mediated mRNA decay. Nonetheless, IKAROS protein expres-
sion levels were, on average, 40% lower in all 3 mutant subjects
compared with the wild-type family members and healthy control
subjects (Fig 1, D). The latter suggests that the mutant transcript
encodes an unstable truncated protein that is rapidly degraded.5
Alternatively, the truncated protein might not be recognized by
the antibody; however, epitope details are lacking. Either way,
our findings indicate a molecular diagnosis of IKAROS haploin-
sufficiency in patients II:3 and II:4 and their asymptomaticmother
(subject I:2). Because the mutation was also present in the clini-
cally asymptomatic 43-year-old subject I:2, we performed in-
depth immunologic testing, which revealed mildly reduced serum
IgM levels, as well as marginally inadequate antibody responses
to a polysaccharide pneumococcal vaccine (see Table E1).
Because germline IKAROS haploinsufficiency is a newly
identified primary immunodeficiency and data on asymptomatic
mutation carriers are scarce, we evaluated the peripheral and
central B-cell compartments both in the affected siblings and their
asymptomatic mother. In patient II:3 the few circulating B cells
consisted for 50% of transitional B cells (Fig 2, B). Total naive B-
cell levels, encompassing transitional B cells, were also increased
at the expense of switchedmemory andmarginal zone B cells (Fig
2, B). In patient II:4 normal numbers of peripheral B-cell subsets
revealed an arrest at a later stage in development. Particularly,
transitional B-cell levels were normal, whereas total naive B-
cell levels were relatively increased and memory-type B-cell per-
centages were decreased (Fig 2,B). This points to a block after the
naive mature B-cell stage. Analogous to previously reported
asymptomatic IKZF1 mutation carriers,2,3 the asymptomatic
mother (subject I:2) exhibited peripheral B-cell frequencies and
subsets within normal range for age, although memory-type B
cells were at the lower end and naive B cells were at the upper
end. This remained stable over a period of about 2 years (Fig 2,B).
Bone marrow aspirates from patient II:3 and the asymptomatic
mother (subject I:2) revealed normal frequencies of hematopoi-
etic stem cells. Multipotent progenitors were reduced, whereas
common lymphoid progenitors weremoderately expanded (Fig 2,
C, and see Fig E3 in this article’s Online Repository at www.
jacionline.org), and total B-lineage cell frequencies were pro-
foundly decreased in both patients (Fig 2, C and D, upper panel).
In addition, symptomatic patient II:3 exhibited a partial block
from pro- to pre-B cells (Fig 2, D, middle panel) and an almost
complete block from immature/transitional to mature B cells
(Fig 2, D, lower panel). In the asymptomatic mother (subject
I:2), on the other hand, the reduced B-lineage cells demonstrated
a normal maturation profile and were sufficient to sustain normal
peripheral B-cell numbers. Patient II:4 was unavailable for bone
marrow analysis.
The multilevel central B-cell developmental block observed
in this IKZF1 family appears later than observed in previously
published IKAROS-haploinsufficient cases.2,3 First, early1
FIG 1. Molecular and functional characterization. A, Pedigree. Squares, circles, and diamonds indicate
male, female, and sex unknown, respectively. Diagonal lines indicate deceased siblings. Corresponding
electropherograms are shown on the right. lab abn., Laboratory abnormalities. B, Schematic structure of
IKAROS isoform 1 (IKZF1 transcript NM_006060).Gray boxes represent exons. Zinc fingers (ZF) 1 to 4 consti-
tute the DNA binding domain, and ZF5 and ZF6 constitute the protein dimerization domain. Previously pub-
lished mutations are depicted in black; 1 family had a large chromosomal deletion (7p12.3-p12.1)
encompassing the IKZF1 gene. The reported novel mutation is indicated in red. C, IKZF1mRNA expression
was determined by means of real-time quantitative PCR of 2 amplicons located upstream and downstream
of the mutation site, respectively. The cDNA start and end position of each amplicon is shown between
brackets (IKZF1 transcript NM_006060). The 2 studied patients (II:3 and II:4) had similar IKZF1mRNA levels
compared with healthy control subjects (HC), indicating that the mutant transcripts escape nonsense-
mediated mRNA decay. The graph represents the mean 6 SD of 1 experiment. ns, Not significant. D,
IKAROS protein expression inmutant (M/WT) and wild-type (WT/WT) family members and 3 healthy control
subjects (HC) analyzed in CD31 T cells by use of flow cytometry. Histograms are depicted on the left. The
graph on the right displays mean 6 SDs of the corresponding mean fluorescence intensity (MFI) values.
Data shown are representative of 2 replicate experiments. FMO, Fluorescence minus one.
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multipotent progenitor and B-lineage stages, whereas 2 patients
reported by Hoshino et al3 exhibited blockages at the earlier he-
matopoietic stem cell and common lymphoid progenitor stages
in addition to the B-lineage block. Second, within B-lineage cells,
symptomatic patient II:3 exhibited arrests at the pre-B and mature
B-cell stages, whereas the Hoshino et al patients showed normal
composition of the B-lineage, and 2 patients described by Kuehn
et al2 had a block at the earlier pro-B cell stage.Whether these dif-
ferences are linked to the genotype of our patients remains to be
established because all 4 previously reported patients harbored
missense mutations in the second zinc finger motif of IKZF1,
whereas our patients have a loss of IKAROS protein caused by
a frameshift mutation.
To our knowledge, there have been no previous reports on
central B-cell development in asymptomatic IKZF1 mutationcarriers. In subject I:2 the absence of clinical involvement was
reflected in a quasinormal peripheral B-cell development. How-
ever, considering the important reduction in central B-lineage
cells and the recently documented specific antibody deficiency,
the B-cell compartment is clearly affected, and the subject might
still become symptomatic at a later age.2 Interestingly, a Kaplan-
Meier curve for onset of symptoms generated based on 45 re-
ported symptomatic and asymptomatic cases suggests that all
germline IKZF1 mutation carriers might eventually go on to
develop symptoms (see Fig E4 in this article’s Online Reposi-
tory at www.jacionline.org). Although Kaplan-Meier estimates
at the utmost ends of a time interval need to be interpreted
with caution, from a clinical perspective, this warrants longitu-
dinal follow-up of asymptomatic subjects. Peripheral B-cell
numbers seem to be a suitable marker for monitoring disease
progression, whereas serum IgG levels have been shown to
FIG 2. B-cell phenotype. A, Peripheral blood total B-cell counts. Measurements shown are from the first to
the last immunologic laboratory evaluation performed in our hospital. Gray shading represents the age-
based reference range. B, Peripheral blood B-cell subsets. The top row depicts total B cells gated as
CD191CD201 in alive PBMCs. In the second and third rows, B-cell subsets were gated on total CD191CD201
B cells, as indicated. Note that samples shown here were taken at different time points than those in Table
E1. C, Overview of different precursor stages of B-cell development in bone marrow shown as a proportion
of total Lin2CD451, CD451, or CD191CD52 cells, as indicated. D, Bone marrow B-cell subsets. The top row
depicts total B-lineage cells gated as CD191CD52 in CD451 cells. In the second and third rows, B-lineage
subsets were gated within this CD191CD52 population. The middle graphs allow discrimination of pro-B
cells (CD341CD191) from more mature B-lineage cells (CD342CD191). The lower graphs show the develop-
ment from pro- and pre-B cells (pro-/pre-B; CD101CD202) over immature and transitional B cells (immature/
trans B; CD101CD201) to mature naive B cells (mature B; CD102CD201). CLP, Common lymphoid progen-
itors; HC, healthy control subject; HSC, hematopoietic stem cells; imm., immature B;MPP, multipotent pro-
genitors;MZB, marginal zone B cells;NB, naive B cells; SMB, switchedmemory B cells; Trans B, transitional
B cells.
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lymphopenia.2
IKAROS haploinsufficiency shares important genetic aspects
with other recently identified primary immunodeficiencies of
haploinsufficiency. Notable are nuclear factor kB1, cytotoxic T
lymphocyte–associated antigen 4, and GATA-2 haploinsufficien-
cies, disorders that also affect the B-cell compartment and are
characterized by incomplete penetrance, as well as variable
expressivity and a highly variable age of onset in manifesting
subjects.6,7 The molecular basis of incomplete penetrance and
variable expressivity is poorly understood.6 Murine models
have implicated an important role for IKAROS at nearly every
step of B-cell development and function.8,9 Besides the more
obvious defects in hematopoietic progenitor cell development,
impaired IKAROS function during recombination of immuno-
globulin gene segments and peripheral B-cell responses might
provide a link with the antibody-mediated autoimmune diseasesseen in patient II:4 and previously reported cases andwith the spe-
cific polysaccharide antibody deficiency detected in the asymp-
tomatic mother (subject I:2), respectively.2,3 Furthermore, the
largely different B-cell profile in the reported mutant subjects
despite similarly low IKAROS protein levels might suggest the
presence of compensatory mechanisms at multiple levels capable
of (partially) surmounting the IKAROS defect.8,9 The actions of
modifier genes, epigenetic changes, and/or environmental expo-
sures might affect these compensatory mechanisms in different
ways, which could, in part, explain the phenotypic heterogeneity
in IKAROS-haploinsufficient patients.8,9 Disease-influencing
mechanisms in IKZF1-associated immunodeficiency await
further study.
In conclusion, we report on the first truncating IKZF1mutation
associated with IKAROS haploinsufficiency and illustrate an un-
expectedly late and variable block in central and peripheral B-cell
development in 2 patients and their asymptomatic mother. Given
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follow-up of asymptomatic IKZF1 mutation carriers.
We thank the patients and their family who participated in this study and
Veronique Debacker, Nancy De Cabooter, and Kelly Heyns for excellent
technical assistance.
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METHODS
Clinical information
The first 2 pregnancies in the index family were complicated by premature
labor of unknown cause at 25 (subject II:1) and 15 (subject II:2) weeks of
gestational age, respectively. Neither child was viable. The 3 remaining sisters
(subjects II:3, II:4, and II:5) were born around 35 weeks of gestational age and
had an uneventful postnatal period.
Ethics
All reported subjects providedwritten informed consent for participation in
the study in accordance with the 1975 Helsinki Declaration. The research
protocol was approved by the ethical committee of Ghent University Hospital
(2012/593).
Whole-exome sequencing
Whole-exome sequencing was performed in the 2 affected siblings
(patients II:3 and II:4) and both parents (subjects I:1 and I:2). Genomic
DNAwas isolated from whole blood leukocytes by using the Puregene DNA
Isolation Kit (Qiagen, Hilden, Germany), according to the manufacturer’s
instructions.Whole-exome enrichment was performedwith the SureSelectXT
Human All Exon V6 kit (Agilent Technologies, Santa Clara, Calif). Paired-
end massively parallel sequencing (150 cycles) was performed on a NextSeq
500 (Illumina, San Diego, Calif). Read mapping against the human genome
reference sequence (National Center for Biotechnology Information,
GRCh37) and postmapping duplicate read removal, quality-based variant
calling, and coverage analysis were performed with CLC Genomics
Workbench v6.0.4 (Qiagen). More than 98% of enriched regions had a read
depth of at least 20. Called variants with a coverage of 3 or greater were
annotated with Alamut Batch (Interactive Biosoftware, Rouen, France). Only
variants with population frequencies of less than 10% were considered,
according to the public databases National Center for Biotechnology In-
formation’s dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/); National
Heart, Lung, and Blood Institute’s Exome Sequencing Project–ExomeVariant
Server (http://evs.gs.washington.edu/EVS/); Exome Aggregation Consortium
Browser (http://exac.broadinstitute.org/); and 1000 Genomes Project Browser
(http://browser.1000genomes.org/). Variants were prioritized further based on
allele frequency, functional prediction scores, nucleotide conservation scores,
and biological relevance.E1 Both Mendelian and non-Mendelian inheritance
patterns were taken into account. Afterward, variants of interest were evalu-
ated by using Alamut Visual mutation interpretation software (v2.7, rev. 1;
Interactive Biosoftware), Ingenuity Variant Analysis (Qiagen, 2015 Release
Spring), CADD scores (v1.3; http://cadd.gs.washington.edu/home), the
Genome Aggregation Database Browser (http://gnomad.broadinstitute.org),
literature search, segregation analysis in available family members, and fre-
quency in an in-house database containing variants of more than 1000 exomes
at the time of analysis.
Sanger sequencing of genomic DNA
The DNA template (GRCh37/hg19) of IKZF1 (NM_006060) was obtained
from the UCSC Genome Browser (https://genome.ucsc.edu). Primers for
amplification and sequencing of exon 3 and adjacent intron-exon boundaries
were designed with Primer3Plus (http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi/)E2: forward primer 59-CTCATGCCACCCTCT-
CAAG-39 and reverse primer 59-GAGTGTCCATCCTCCCACAC-39.
Genomic DNA was amplified by mean of PCR using the specific primers
and KAPA2G Robust Hotstart Ready Mix (KAPA Biosystems, Wilmington,
Mass). PCR products were enzymatically purified with Exonuclease I and
Antarctic phosphatase (both fromNew England BioLabs, Ipswich, Mass). Pu-
rified PCR products were sequenced with the BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, Calif) on a 3730xl DNA
Analyzer (Applied Biosystems). Sequence reads were analyzed with Seq-
Scape v2.5 (Thermo Fisher Scientific, Waltham, Mass).
Sanger sequencing of cDNA
Total RNA was isolated from PBMCs of all available family members
(subjects I:1, I:2, II:3, II:4, and II:5) and 2 healthy control subjects by using the
RNeasy PlusMini Kit (Qiagen) and reverse transcribed with the iScript cDNA
synthesis kit (Bio-Rad Laboratories, Hercules, Calif), according to the
manufacturer’s instructions. The cDNA template (GRCh37/hg19) of IKZF1
(NM_006060) was obtained from the Ensembl Genome Browser (http://
www.ensembl.org/index.html). Primers for amplification and sequencing of
exon 3 and adjacent coding regions were designed with Primer3Plus (http://
www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/)E2: forward
primer 59-ATGGATGCTGATGAGGGTCAAG-39 and reverse primer 59-
CGGAATGCAGCTTGATGTGCAGGAGC-39. PCR amplification was per-
formed by using GoTaq Hot Start Colorless Master Mix (Promega, Madison,
Wis). Purified PCR products were Sanger sequenced with the BigDye Termi-
nator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3130xL Genetic
Analyzer (Applied Biosystems). Sequence reads were analyzed with SeqMan
(DNASTAR, Madison, Wis).
IKZF1 gene expression
Total RNAwas isolated fromPBMCs of 2mutant familymembers (II:3 and
II:4) and 3 healthy control subjects by using the RNeasy Plus Mini Kit
(Qiagen) and converted to cDNA by using the Transcriptor High Fidelity
cDNA Synthesis Kit (Roche, Mannheim, Germany), according to the
manufacturer’s instructions. Two amplicons of IKZF1 were investigated: am-
plicon 1 located upstream of the mutation at genomic position
Chr7:50358652-50367269 and amplicon 2 located downstream of the muta-
tion at genomic position Chr7:50469628-50469734 (GRCh37/hg19). These
amplicons were chosen to target as many IKZF1 transcripts as possible.
Primers were designed by using PrimerXL and IDT PrimerQuest (available
on request). GPI and PSMB2 were used as reference genes. Gene expression
was analyzed by using real-time quantitative PCR with LightCycler 480
SYBR Green I Master reagent and a LightCycler 96 Instrument (both from
Roche), according to the manufacturer’s instructions. All reactions were per-
formed in triplicate. The relative quantification of gene expression was calcu-
lated with the comparative cycle threshold method.
Flow cytometric analysis of peripheral blood B- and
T-cell subsets
Peripheral blood B- and T-cell subsets were evaluated in the IKZF1 muta-
tion carriers (subjects I:2, II:3 and II:4) and age-matched healthy control sub-
jects, as previously described.E3 In brief, cryopreserved PBMCs were stained
with Fixable Viability Dye 506 (eBioscience, San Diego, Calif) and fluores-
cently labeled mAbs under saturation conditions. The following antibodies
(clones) were used: CD8 (RPA-T8), CD16 (3G8), CD19 (HIB19), CD20
(2H7), CD21 (B-LY4), CD27 (M-T271), CXCR5 (RF8B2), IgD (IA6-2),
and gd T-cell receptor (11F2; all from BD Biosciences, San Jose, Calif);
CD3 (SK7), CD4 (SK3), CD24 (ML5), CD25 (BC96), CD45RO (UCHL1),
and CCR7 (G043H7; all from BioLegend, San Diego, Calif); CD4 (RPA-
T4), CD38 (HIT2), CD56 (TULY56), and forkhead box protein 3 (Foxp3;
PCH101; all from eBioscience). Cells were acquired on an LSR Fortessa
flow cytometer (BD Biosciences). Data were analyzed with FlowJo software
(version X; TreeStar, Ashland, Ore).
IKAROS intracellular staining
Cryopreserved PBMCs were first stained with fluorescently labeled anti-
CD3 (clone UCHT1) and anti-CD19 (clone SJ25C1; both from BD Bio-
sciences). Afterward, cells were fixed and permeabilized with the FoxP3
staining kit (eBioscience), according to the manufacturer’s instructions, and
incubated with fluorescently labeled anti-IKAROS (clone R32-1149; BD
Biosciences).E4 Cells were acquired on a FACSCanto II flow cytometer (BD
Biosciences). Data were analyzed with FlowJo software (version X;
TreeStar).
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Flow cytometric analysis of bone marrow aspirates
Bone marrow aspirates from the hipbone were obtained from subjects
I:2 and II:3 with informed consent and ethical approval of the Newcastle
and North Tyneside Research Ethics Committee. Human bone marrow
control samples were obtained from a femoral head after total hip
replacement with informed consent and ethical approval of Newcastle and
North Tyneside Research Ethics Committee. The femoral head was
excavated, the cavity and fragments were washed with PBS, and it was
then passed through a 50-mm filter to obtain cells from the hip
arthroplasty specimen. Mononuclear cells were prepared from the
resulting cell suspension by using density centrifugation and stained for
flow cytometry according to standard protocols.
Analysis of hematopoietic stem and lineage progenitor cells was based on
the method of Doulatov et al.E5 The following antibodies (clones) were used:
CD3 (SK7-Leu9), CD19 (HIB19), CD20 (L27), CD56 (NCAM16.2), CD38
(HB7), CD45RA (HI100), CD90 (G20-127), and CD10 (HI10A; all from
BD Biosciences) and CD34 (581; BioLegend). Cells were acquired on an
LSR Fortessa X-20 flow cytometer (BDBiosciences), with dead cell exclusion
by using 49-6-diamidino-2-phenylindole dihydrochloride (Sysmex, Lincoln-
shire, Ill).
For analysis of B-lineage cells, cryopreserved bone marrow samples were
stained, as previously described.E6 The following antibodies (clones) were
used: CD5 (L17F12), CD10 (HI10a), CD19 (SJ25C1), CD20 (2H7), CD45
(2D1), CD34 (8G12); all from BD Biosciences). Samples were acquired on
a FACSCanto II flow cytometer (BD Biosciences).
All data were analyzed with FlowJo software (version X; TreeStar).
Statistical analysis
IKZF1 gene expression and IKAROS protein expression levels were
compared by using the Mann-Whitney U test with GraphPad Prism software
(v7; GraphPad Software, La Jolla, Calif). A 2-sided P value of .05 or less was
considered statistically significant.
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FIG E1. Peripheral blood T-cell subsets. Flow cytometric immunophenotyping of T-cell subsets was
performed on patients’ PBMCs in comparison with age-matched healthy control subjects (HC). At the time
of analysis, subjects I:2, II:3 and II:4 were 40, 14, and 9.5 years old, respectively. Patient II:3 is indicated as a
purple triangle, and patient II:4 is indicated as a blue star. Total T cells were gated as CD31 in alive PBMCs.
ab T cells were gated as gd T-cell receptor2negative in total T cells. CD41 and CD81 T cells were gated in ab
T cells. In CD41 and CD81 T cells naive cells were gated as CD45RO2CCR71, central memory cells (TCM) as
CD45RO1CCR71, effector memory cells (TEM) as CD45RO1CCR72, and terminally differentiated cells
(TEMRA) as CD45RO2CCR72. Regulatory T (Treg) cells were gated as CD251Foxp31 and circulating follic-
ular helper T (cTfh) cells were gated as CXCR51CD45RO1 in CD41 T cells. Double-negative (DN) T cells
were gated as CD42CD82 in ab T cells. Natural killer (NK) T cells were gated as CD561 in total CD31 T cells.
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FIG E2. IKZF1 cDNA sequencing. Representative IKZF1 cDNA sequences of
a mutant (M/WT) and wild-type (WT/WT) family member. cDNA was
derived from total PBMCs. The position of the nucleotide deletion (c.136)
is shown at the top. The M/WT subject has both a mutant and a wild-type
cDNA sequence, suggesting that the mutant transcripts escape nonsense-
mediated mRNA decay.
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FIG E3. Flow cytometric analysis of hematopoietic stem and early lineage progenitor cells in the bone
marrow. The gating strategy was based on the method of Hoshino et al.E10 Percentages are percentages of
the parent population, indicated at the top of each plot. CLP, Common lymphoid progenitor; HSC, hemato-
poietic stem cell; MPP, multipotent progenitor.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
LETTER TO THE EDITOR 4.e5
FIG E4. Kaplan-Meier curve on symptom-free survival in germline IKZF1
mutation carriers. The curve was generated based on the presence and
age of onset of clinical symptoms in the 42 previously published cases
and the 3 reported cases with germline heterozygous IKZF1 mutation-
s.E4,E10,E11 Manifesting subjects first presented with symptoms up to the
age of 57 years. Asymptomatic cases were 50 years or younger at time of
publication (ie, censored subjects, as indicated on the curve as black tick
marks). The Kaplan-Meier symptom-free survival curve estimates that all
IKZF1 mutation carriers will have symptoms by 57 years of age.
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TABLE E1. Routine immunologic laboratory evaluation
White blood cells
Subject II:3 Subject II:4 Subject I:2
Value
Reference
range Value
Reference
range Value
Reference
range
Age: 13 y Age: 11 y Age: 42 y
Total leukocytes (no./mL) 6,820 4,500-12,000 5,050 4,500-12,000 11,320 3,650-9,300
Neutrophils (no./mL) 3,580 2,500-8,000 2,240 2,500-8,000 7,850 1,573-6,100
Lymphocytes (no./mL) 1,690 1,500-6,500 2,030 1,500-6,500 2,350 1,133-3,105
CD31 T cells (no./mL) 1,370 800-3,500 1,520 800-3,500 1,930 700-2,100
CD31CD41 TH cells (no./mL) 659 400-2,100 771 400-2,100 1,030 300-1,400
CD45RA1 naive CD41 T cells (%) 32 33-66 52 46-77 24 NA
CD45RO1 memory CD41 T cells (%) 60 18-38 34 13-30 72 NA
CD31CD81 T cytotoxic cells (no./mL) 575 200-1,200 508 200-1,200 729 200-1,200
CD45RA1 naive CD81 T cells (%) 63 61-91 80 63-92 47 NA
CD45RO1 memory CD81 T cells (%) 32 4-23 16 4-21 53 NA
Ratio CD4/CD8 1.15 0.9-3.4 1.52 0.9-3.4 1.42 1.0-3.6
CD191 B cells (no./mL) 17 200-600 122 200-600 141 100-500
IgD1CD272 naive B cells (%) 93 51.3-82.5 90 51.3-82.5 77 48.4-79.7
CD2411CD3811 transitional B cells (%) 50 1.4-13.0 3 1.4-13.0 1 0.9-5.7
IgD2CD271 switched memory B cells (%) 1.5 8.7-25.6 3 8.7-25.6 10 8.3-27.8
IgD1CD271 marginal zone B cells (%) 2 4.6-18.2 2 4.6-18.2 9 7.0-23.8
CD21lowCD38low B cells (%) 3 2.7-8.7 3 2.7-8.7 3 1.6-10.0
CD32CD561CD161 NK cells (no./mL) 304 70-1,200 386 70-1,200 259 90-600
Monocytes (no./mL) 730 500-1,000 650 500-1,000 820 247-757
Eosinophils (no./mL) 300 100-500 20 100-500 240 28-273
Basophils (no./mL) 30 10-100 80 10-100 30 6-50
Immunoglobulins* Age: 9 y Age: 11 y Age: 42 y
IgG (g/L) 7.0 4.70-11.9 12.7 4.70-11.9 10.7 7.0-16.0
IgG2 (g/L) 1.3 0.98-4.8 3.69 0.98-4.8 2.09 1.50-6.40
IgG3 (g/L) 0.668 0.15-1.49 0.309 0.15-1.49 0.617 0.20-1.10
IgM (g/L) Undetectable 0.27-0.74 0.4 0.27-0.74 0.35 0.40-2.48
IgA (g/L) Undetectable 0.50-1.66 Undetectable 0.50-1.66 0.98 0.71-3.65
IgE (kU/L) <4.4 0-90 44.2 0-90 <4.4 0-100
Specific antibody responses* Age: 9 y Ages: 5 and 7 y Age: 42 y
Streptococcus pneumoniae polysaccharide
IgG (Lab U)
<3 >_11: immune 3 >_11: immune NA
S pneumoniae polysaccharide IgG: specific
IgG response to 3 serotypes (8, 9N, 15B)
NA Insufficient
antibody
responses
Adequate titer
increase for >_2
of 3 serotypes§
Borderline
insufficient
antibody responses
Adequate titer
increase for >_2
of 3 serotypes§
Tetanus IgG (IU/mL) 1.0 >_0.01: immune 0.3 >_0.01: immune 0.01 >_0.01: immune
Rubella IgG (IU/mL) 18 >10: immune 68 >10: immune NA
Measles IgG (mIU/mL) 610 >300: immune 1,000 >300: immune NA
Mumps IgG (Lab U/mL) 1800 >500: immune <230 >500: immune NA
Varicella zoster IgG (mIU/mL) 580 >100: immune 1,900 >100: immune NA
Lymphocyte proliferation assay Age: 9 y Age: 5 y
Response to concanavalin A Normal Compared with
control
Normal Compared with
control
NA
Response to PHA Normal Compared with
control
Normal Compared with
control
NA
Response to tetanus toxoid Moderately
reduced
Compared with
control
Normal Compared with
control
NA
The most recent, comprehensive, and representative laboratory results are shown for each patient, with patient age at the time of analysis mentioned. Patients II:3 and II:4 were
immunized according to the recommended childhood immunization schedule that, among others, included tetanus, measles, mumps, rubella, and 7-valent conjugated
pneumococcal vaccines. Subject I:2 received a tetanus booster vaccine within the last 10 years. A polysaccharide (unconjugated) pneumococcal vaccine was given to all 3 subjects
at the time of immunologic evaluation; subject I:2 had never received a pneumococcal vaccine before then. Patients II:3 and II:4 were not vaccinated against varicella-zoster virus
but had chickenpox in early childhood.
Lab U, Laboratory units; NA, not available.
*Measured before the start of immunoglobulin replacement therapy.
Reference values from Shearer et al.E7
Reference values from Piatosa et al.E8
§In accordance with the recommendations of Orange et al.E9
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